Initiating Coverage
​BRASTER S.A. is a company, which develops a telehealth device that allows non-invasive, early-stage detection of breast cancer.
Braster SA is a Poland-based company principally engaged in the bio diagnostics and testing. The Company provides research and development on breast cancer. Braster SA applies liquid crystals and liquid crystal emulsion formula that is used to produce liquid crystal matrix based on LCD technology, continuous film CLCF (Continuous Liquid Crystal Film) in the diagnosis of breast cancer. Its main product is Braster Tester, which is a device that uses thermographic liquid crystal matrices for diagnosing breast cancer; the device is made up of three film matrices covered with a liquid crystal mixture that allows thermal imaging. The Company cooperates with the Jagiellonian University, with the participation of the clinical trial conducted by THERMACRAC, among others.
We are a leading, management-owned research boutique with a focus on companies from Emerging Europe. Our role is that of an intermediary between companies on the one hand and investors on the other. Our research products are directly distributed to more than 200 mutual and pension funds, family offices and independent asset managers from Central and Eastern Europe, the German-speaking region, Scandinavia, France and UK. In addition, we publish our reports on platforms such as Bloomberg, Thomson Reuters, Capital IQ and PAP, thus ensuring that they are available to institutions from around the world. By organising roadshows and conferences, we provide investors with direct access to corporate decision makers. Our team consists of professionals with long capital market experience in both Western Europe and the CEE region.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.